{"id":"W2591748434","doi":"10.1093/annonc/mdx079","title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nilotinib; Dacarbazine; Melanoma; Internal medicine; Clinical endpoint; Imatinib; Oncology; Progressive disease; Tyrosine-kinase inhibitor; Phases of clinical research; Adverse effect; Gastroenterology; Randomized controlled trial; Surgery; Clinical trial; Chemotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154314,0.001236937,0.002076569,0.0002251457,0.0002168496,0.00117593,0.0004895325,0.0007779374,0.001538028],"category_scores_gemma":[0.001002552,0.0003032248,0.002133585,0.0002645048,0.00083031,0.001238085,0.0003759156,0.002237656,0.0004962511],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006643485,"about_ca_system_score_gemma":0.0006382515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003636388,"about_ca_topic_score_gemma":0.001413678,"domain_scores_codex":[0.9996454,0.0001879927,0.00001645524,0.00006210159,0.00002636628,0.00006175597],"domain_scores_gemma":[0.9995443,0.0001059746,0.0001193245,0.00003111107,0.00003004137,0.0001693088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7915498,0.004656001,0.01474473,0.002225311,0.007637103,0.0002794835,0.0002092342,0.004097895,0.01444321,0.0004172747,0.007528299,0.1522117],"study_design_scores_gemma":[0.7801909,0.1640783,0.03653752,0.0003119531,0.004988458,0.0008511524,0.0002263567,0.002845105,0.002691024,0.001524395,0.005651823,0.0001030685],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849861,0.01026611,0.0004596703,0.00086119,0.0002082413,0.0002409323,0.000744011,0.00009641582,0.002137479],"genre_scores_gemma":[0.9919264,0.0033489,0.0004888889,0.00110595,0.0001484493,0.0002777494,0.001425358,0.00003429535,0.001244133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002076569,"threshold_uncertainty_score":0.006104708,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1093013030122073,"score_gpt":0.3778659373283518,"score_spread":0.2685646343161445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}